Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study
Clinical and Applied Thrombosis/Hemostasis · 2026
DOI: 10.1177/10760296251413253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2026. Verfasst von Zhiqiang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, the Fuyang Affiliated Hospital of Anhui Medical University, Fuyang, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Venous Thromboembolism, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Anhui Provincial Health Commission Scientific Research Project.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
The risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD), especially when receiving treatment with Janus kinase inhibitors (JAKi), has been reported in observational studies. however, the causal relationships between them remain unclear. We aim to explore the causal effects of AD and JAKi on VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Methods
Two-sample Mendelian randomization (MR) analyses were conducted to examine the causal between genetic susceptibility to AD or JAKi target genes (including JAK1, JAK2, JAK3 and tyrosine kinase 2 [TYK2]) and VTE (encompassing DVT and PE) using summary statistics from genome-wide association studies and eQTLGen project. Inverse variance weighting with random effect method was used as the main analytic approach. Pleiotropy and heterogeneity tests were conducted to assess the robustness of the findings.
Results
No significant causal effects were found between AD and the risk of (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.91-1.03, P = .352), DVT (OR: 0.99, 95% CI: 0.89-1.10, P = .789), and PE (OR: 1.06, 95% CI: 0.93-1.20, P = .387). Similarly, there was no causal association between the expression of JAK1, JAK2, JAK3 or TYK2 and VTE, DVT and PE.
Conclusion
The MR analysis revealed no genetic causal relationships between either AD or JAKi target genes and VTE. These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, the Fuyang Affiliated Hospital of Anhui Medical University, Fuyang, China.
- College of Clinical Medicine, North Henan Medical University, Xinxiang, China.
- Department of Dermatology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
ORCID-Profile: Yifei Wang
Förderung
- Anhui Provincial Health Commission Scientific Research Project
Zitieren
APA
Chen, Z., Wang, S., & Wang, Y. (2026). Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296251413253
Vancouver
Chen Z, Wang S, Wang Y. Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. Clinical and Applied Thrombosis/Hemostasis. 2026. doi:10.1177/10760296251413253
BibTeX
@article{Chen2026,
author = {Chen, Zhiqiang and Wang, Shuaibo and Wang, Yifei},
title = {Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
doi = {10.1177/10760296251413253}
}
EUVIMED